DATE:  November 1, 2017

TIME:  9:00am PT, 12:00pm ET

Over 1.6 million people are diagnosed with sepsis in the U.S. each year¹ and sepsis is the #1 cost of hospitalization (over $24 billion each year)¹. Having a biomarker that can quickly identify sepsis is critical because mortality increases 8% every hour that treatment is delayed¹.

Procalcitonin (PCT) helps determine if the patient has a bacterial infection (sepsis), the severity of the infection and is the patient responding to therapy². PCT is a more accurate diagnostic parameter for sepsis and a better predictor of mortality and a more reliable marker than other biomarkers³. PCT also provides clinicians a mechanism for antibiotic stewardship².

1. Sepsis Alliance Website: http://www.sepsis.org/downloads/2017_sepsis_facts_media.pdf3
2. Thermo Scientific B-R-A-H-M-S PCT Improving infection management.
3. Shiferaw, et al. The Role of Procalcitonin as a Biomarker in Sepsis. J Infect Dis Epidemiology. 2016;2:006 Vol 2.

Expected Outcomes:

• Understand the clinical utility of PCT.
• Incorporate  PCT protocols as part of sepsis management.
• Demonstrate the impact PCT can have on clinical and financial outcomes